Objectives: The prognosis in lung cancer patients with a prior history of extrapulmonary cancer is controversial. In the current multicenter joint research in Japan, we focused on the relationship between a history of colorectal cancer and its prognostic impact in patients with subsequent lung cancer. Methods: Between 2000 and 2013, we designed a retrospective multicenter study at three institutes in Japan to evaluate the prognostic factors in lung cancer patients with a previous surgery for colorectal cancer. Results: The cohorts consisted of 123/4431 lung cancer patients with/without a previous history of surgery for colorectal cancer. The median follow-up period was 6.1 years after lung cancer surgery. The 5-year overall survival in lung cancer patients with/without colorectal cancer was not significantly different, regardless of the stage of lung cancer (overall: 71.3 versus 74.7%, P ¼ 0.1426; Stage I lung cancer: 83.3 versus 84.8%, P ¼ 0.3779; Stage II or more lung cancer: 47.7 versus 54.4%, P ¼ 0.1445). Based on multivariate Cox regression analysis in 4554 lung cancer patients, a past history of colorectal cancer was not a significant prognostic factor (P ¼ 0.5335). Among the 123 lung cancer patients with colorectal cancer, age and absence of adjuvant chemotherapy for colorectal cancer were significant prognostic factors based on multivariate analysis (P ¼ 0.0001 and 0.0236). Furthermore, there was no difference in the overall survival of lung cancer patients according to the stage of colorectal cancer (Stage I: 74.7%; Stage II/III: 66.5%, P ¼ 0.7239). Conclusions: A history of antecedent colorectal cancer did not contribute to the prognosis in patients with subsequent lung cancers.
INTRODUCTION
Lung cancer is the most frequent cause of major cancer and the leading cause of death worldwide (1, 2) . Due to recent developments in imaging technology and the widespread use of thin-section computed tomography (CT) for the screening of lung cancer, it is expected that the incidence of lung cancer will increase as a direct result of screening examinations (3) . Furthermore, this will lead to an increase in the identification of early-stage lung cancers and a consequent later decrease in mortality.
The risk of developing a new malignancy in patients with an unrelated previous cancer has been reported to be 5 -15 times higher than that in the general population (4) . As a result of the increasing incidence of any cancers due to improved treatment modalities and long-term survival worldwide (5), we often encounter newly detected lung cancer patients with a prior history of extrapulmonary cancers, especially gastrointestinal lesions (6 -10) . Among these, colorectal cancer accounts for a high percentage of both incidence and death worldwide and is associated with lung cancer as a multiple primary malignancy (11 -13) . Many studies have reported several clinical, radiological, pathological and molecular factors that predict the prognosis in lung cancer patients (2, 14, 15) . However, despite remarkable advances in our understanding of lung cancer over the past decade, it is not yet clear whether a history of previous treatment for any other cancers, especially colorectal cancers, affects the prognosis of surgery for lung cancer. In this study, we highlighted colorectal cancer, because it is a common malignancy and fatality rates are high (13) . The incidence of multiple primary cancers in patients with colorectal cancer is 15 -20%, and the incidence of lung cancer is the second next to stomach cancer of these patients in the past literature (12) . On the other hand, a few studies have addressed the clinical behavior and survival of small cohorts of patients with non-small cell lung cancer who had previously been treated for colorectal cancer. Thus, we evaluated the survival and prognostic factors of lung cancer patients with the past history of colorectal cancer.
At any single institution, the number of patients with a previous history of colorectal cancer is relatively small. Therefore, the purpose of this study was to investigate the clinicopathological impact of preceding surgery for colorectal cancer in patients with lung cancer by multi-institutional joint research in Japan.
PATIENTS AND METHODS

APPROVAL
This was a multi-institutional joint research study (Juntendo University School of Medicine, IRB No. 13 -133; National Cancer Center Hospital East, IRB No. 2013-106; Hiroshima University Hospital, IRB No. eki-862). The study protocol was approved by the institutional review boards of the three participating institutes. Due to a retrospective study, the need to obtain written informed consent from each patient was waived.
PATIENTS
Based on their cancer history, patients were categorized as either lung cancer patients with previous surgery for colorectal cancer, or those without a history of colorectal cancer. A history of colorectal cancer was confirmed when they were diagnosed or treated for lung cancer at our institutes, otherwise documentation was obtained from other hospitals or clinics. Between January 2000 and June 2013, there were 123 lung cancer patients with a history of preceding surgery for colorectal cancer at our three institutes. The sufficient information regarding their history of colorectal cancer was included in the primary analysis as lung cancer patients with a history of preceding surgery for colorectal cancer. In contrast, we enrolled 4431 lung cancer patients without a history of colorectal cancer as a control group. All patients underwent surgical operation for lung cancer at each institute.
DEMOGRAPHIC DATA
In all cases, the medical record of each patient was reviewed with regard to age, gender, serum carcinoembryonic antigen level (ng/ml, CEA) and several clinicopathological characteristics to evaluate the prognostic factors and elucidate whether the treatment history for colorectal cancer influences the prognosis of subsequent lung cancer surgery. The clinical and pathological stages of each disease were determined based on the International Union Against Cancer, 7th edition (16) .
OPERATION POLICY
Regarding the operative modes for lung cancer, each institute had a consensus that major lung dissection with systemic lymph node dissection is the standard procedure for resectable non-small cell lung cancer despite a previous history of colorectal cancer. Segmentectomy is indicated in part for lung cancers 2 cm or less in size with ground-glass opacity dominant lesion. Nonanatomic wedge resection is also performed for a few elderly patients or for patients with high cardiopulmonary risk.
STATISTICS
In the statistical analysis, the Chi-square test or unpaired t-test were used to compare two factors. Cumulative survival rates for each group, i.e. lung cancer patients with or without a history of colorectal cancer, were calculated by the KaplanMeier method, where the date of surgical resection for lung cancer was used as the starting point and the date of death due to any cause or the date of the last follow-up was used as the end point. The interoperative interval was calculated from the date of surgical resection for colorectal cancer to that for lung cancer. Univariate and multivariate analyses were used to identify clinicopathological factors that significantly predicted the prognosis in patients with or without preceding surgery for colorectal cancer. A univariate analysis was performed by the log-rank test. A multivariate analysis was performed by the Cox proportional hazard model using SPSS Statistics 21 (SPSS Inc.). Forward and backward stepwise procedures were used to determine the combination of factors that were essential for predicting the prognosis. Continuous data are shown as the mean and standard deviation for normality. The results of the statistical analysis were considered to be significant when the probability value was ,0.05.
RESULTS
The clinicopathological characteristics of the entire population are shown in Table 1 . The average age was 70 years (range, 46 -89) in patients with colorectal cancer, and 66 years (range, 20 -93) in those without colorectal cancer (P , 0.0001). Among the 123 lung cancer patients with colorectal cancer, 91 (74.0%) were men and 32 (26.0%) were women, whereas among the 4431 patients without colorectal cancer, 2713 (61.2%) were men and 1718 (38.8%) were women, and this was a significant difference between the groups (P ¼ 0.0041). With regard to the clinical stage of lung cancer, the patients with the past history of colorectal cancers showed significantly early-stage disease of lung cancer (P ¼ 0.0039). A previous history of any organ cancer, including colorectal cancer, was observed in 473 (10.4%) of the total patients. The median follow-up period among the overall patients was 6.1 years after lung cancer surgery (range, 0 -11.8 years). In lung cancer patients with a past history of colorectal cancer, the median time interval from the date of operation for colorectal cancer to that for lung cancer was 2.4 years (range, 0 -25.1 years). The frequencies of adjuvant chemotherapy for lung cancer and the absence of malignancies other than lung and colorectal cancer were significantly higher in lung cancer patients without a history of colorectal cancer (P ¼ 0.0014 and 0.0022, respectively).
Based on univariate and multivariate analyses in 4554 patients with surgically resected lung cancers, gender, age at lung cancer surgery, the presence of any cancers other than those of the lung and colorectum, the pathological stage of lung cancer and the administration of adjuvant chemotherapy for lung cancer were significant prognostic factors in this population, whereas a history of surgery for colorectal cancer was not a predictor in multivariate analysis (P ¼ 0.7793) ( Table 2) .
The overall survival (OS) curves of the populations with and without colorectal cancer are presented in Fig. 1 . As shown in Table 2 , significant differences were not observed between these two groups; however, the 5-year OS in lung cancer patients with colorectal cancer (71.3%) was slightly inferior to that in patients without colorectal cancer (74.7%) (P ¼ 0.1426). Moreover, we evaluated the OS of lung cancer patients with and without colorectal cancer based on the lung cancer staging. According to the results, the OS was not significantly different regardless of the presence of colorectal cancer in patients with both pathological Stage I and Stage II or more lung cancer [Stage I lung cancer (Fig. 2, The clinicopathological characteristics of lung cancer patients with a previous surgery for colorectal cancer are shown in Table 3 . Of the 123 patients, 66 (53.7%) showed colorectal cancer of pathological Stage I. The mean interoperative interval from colorectal cancer to lung cancer was 3.9 + 4.4 years (range, 0 -25.1 years). Adjuvant chemotherapy for colorectal cancer was administrated to 33 (26.8%) patients. With regard to the cause of death, death due to lung 
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Lung cancer with previous colorectal cancer cancer was observed in 18 patients, whereas only 1 patient died because of the recurrence of colorectal cancer. Based on multivariate analysis for lung cancer patients with previous surgery for colorectal cancer, age at the operation for lung cancer and the absence of adjuvant chemotherapy for colorectal cancer were significant prognostic factors (P ¼ 0.0001 and 0.0236, respectively) ( Table 4) . We excluded these two prognostic factors from the cohort of patients with colorectal cancer and re-evaluated the OS. Based on the results, the 5-year OS for all lung cancer patients with colorectal cancers, excluding those .76 years old (the 5-year OS ¼ 77.0%, P ¼ 0.8499), and excluding those who were given adjuvant chemotherapy for colorectal cancer (the 5-year OS ¼ 76.0%, P ¼ 0.4434) compared with those in patients without colorectal cancer (the 5-year OS ¼ 74.7%) were almost equivalent.
With regard to the OS of lung cancer patients with colorectal cancer based on their pathological status, the 5-year OS of lung cancer patients with pathological Stage I colorectal cancer (74.7%) was better than that of lung cancer patients with pathological Stage II or III colorectal cancer (66.5%), although a significant difference was not observed with regard to the stage of colorectal cancer ( Fig. 4 ; P ¼ 0.7239). Furthermore, we evaluated the prognostic factors for OS in lung cancer patients with a previous surgery for pathological Stage I colorectal cancer (n ¼ 66). Based on multivariate analysis, age at the operation for lung cancer and the recurrence of colorectal cancer were significant prognostic factors in these populations (P ¼ 0.0298 and 0.0285, respectively) ( Table 5) .
DISCUSSION
Colorectal carcinoma is one of the most frequent major cancers that are seen with lung cancer (8,11,12,17 ), but the 
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clinicopathological features and the impact of past cancer history on the prognosis of lung cancer have been barely validated. Because the number of lung cancer patients complicated with a previous history of colorectal cancers is increasing, there is an urgent need for a study on this topic.
In the current retrospective multicenter study, we focused on the relationship between a history of antecedent colorectal cancer and its prognostic impact in patients with subsequent lung cancer. With regard to the presence of a past history of any cancers within the previous 5 years in patients with lung cancer, one of the most important points is that this is considered to be an indispensable exclusion criterion in many prospective trials in lung cancer, which could result in a reduction in enrolling the possible candidates. Some reports have indicated that lung cancer patients with preceding cancers in other organs have a poor prognosis (8 -10) . However, the clinicopathological features of and prognosis in lung cancer patients with a prior history of cancer are not fully resolved yet. Furthermore, recent developments in imaging technology and the widespread use of thin-section CT for screening have made it possible to detect early-stage lung cancers (2, 18) . Amid a paradigm shift regarding the stage of lung cancer patients, little information is available regarding the prognostic factors in lung cancer patients combined with a previous surgery for some other malignancy, especially for major cancers like cancers of the colon and rectum.
Based on our study, a history of previous surgery for colorectal cancer did not contribute to the prognosis in the overall lung cancer patients. Furthermore, multivariate analysis revealed that age at lung cancer surgery and the absence of adjuvant chemotherapy for colorectal cancer were significant prognostic factors in 123 lung cancer patients with a previous surgery for colorectal cancer. In this study, the frequencies of lung cancer death, colorectal cancer death and cancer nonrelated death are almost equivalent in lung cancer patients with a past history on colorectal cancer, despite the presence or absence of adjuvant chemotherapy for colorectal cancer. However, the patients administrated adjuvant chemotherapy for colorectal cancer belonged to more advanced stage of colorectal cancer, and the general conditions might be inferior to the patients without adjuvant chemotherapy for colorectal cancer, which influenced to the survival of lung cancer patients. These findings might reflect the poor general status of some colorectal cancer patients performed adjuvant chemotherapy. Interestingly, when these prognostic factors were excluded, the OS rates in lung cancer patients with and without colorectal cancer were almost equivalent by the Kaplan -Meier method. These results obtained from the overall cohort were almost the same as those in lung cancer patients with pathological Stage I colorectal cancer based on the multivariate analysis. Some of the results given above are particularly noteworthy. In particular, a history of colorectal cancer may not contribute to the prognosis in patients with subsequent lung cancers if the lung cancer patients are of a suitable age or if their preoperative status could be well managed by surgery for their previous colorectal cancer.
In a recent study, the pathological stage of colorectal cancer was not a significant predictor in patients with subsequent lung cancer. This is partly due to the retrospective nature of this study, and selection of the candidates for a lung cancer 
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Lung cancer with previous colorectal cancer surgery may be very strict in patients with the history of colorectal cancer. Generally, patients with pathological Stage I or II colorectal cancer have a good prognosis with the 5-year survival rate of 90% (19) . Even pathological Stage IIIA colorectal cancer showed the 5-year survival rate over 70% (19) . It is easy to understand that this study population of patients with pathological Stage III colorectal cancers was a relatively minor and may have included many otherwise healthy patients. Furthermore, with the advances in diagnostic modalities such as thin-section CT scan or positron emission tomography, early detection of lung cancer may be possible and also contribute to favorable outcomes by decreasing the risk of uncontrolled colorectal cancer. Therefore, the presence of a past history of colorectal cancer treatment had relatively little effect on lung cancer prognosis if the patients were appropriately selected. Moreover, with regard to the relationship between a preceding malignancy and subsequent lung cancer, several previous reports described a significant correlation between a history of preceding extrapulmonary malignancy and the early stage of lung cancer (20 -22) . On the other hand, there seemed to be no close relationship between the pathological stage of colorectal and lung cancer in the current study. If anything, the frequency of pathological Stage I lung cancer in patients with a previous history of pathological Stage II or more colorectal cancers (42/57; 73.7%) was somewhat greater than that in patients with pathological Stage I disease (46/66; 69.7%). These results suggest that more intensive follow-up and examinations are needed for more advanced colorectal lesions compared with early-stage disease.
In this study, the interoperative interval from colorectal cancer to lung cancer did not influence the prognosis of lung cancer patients. We selected 5 years as a cutoff value for the interoperative interval, since this value has often been used as an exclusion criterion in prospective studies worldwide. This lack of a relationship was also supported by multivariate analysis, even when we treated the interoperative interval as a continuous value. These results support our opinion that surgery for lung cancer patients with a previous history of colorectal cancer is feasible in adequately selected cohorts.
A major limitation of this study is its retrospective nature. Patient selection for the surgery of lung cancer may be strict among the presence of a previous history of colorectal cancer in each institute. In addition, although we have standard treatment strategies for lung cancer surgery, the indications for each surgical mode may be somewhat different in each institute in accordance with the patient characteristics. Thus, further prospective studies will be necessary in a larger number of patients. Despite these limitations, however, we believe that this study can be helpful in daily clinical practice and in the decision-making process of thoracic surgeons when we encounter lung cancer patients with a history of surgery for colorectal cancer. We believe that our findings address an important issue regarding the clinical trials of lung cancers. In the future, further study is warranted regarding lung cancer patients with any extrapulmonary malignancies to evaluate the clinical behavior and survival of these patients in a prospective setting.
In conclusion, as a result of long-term survival and sufficient follow-up, the incidence of lung cancer in patients with a history of colorectal cancer has changed dramatically over time. Thus, a history of antecedent colorectal cancer did not contribute to the prognosis in patients with subsequent lung cancers. In the future, a multidisciplinary team management approach may be essential for developing customized treatment strategies in patients with lung cancer associated with antecedent colorectal cancer.
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